Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Veerle I.j. Bossuyt, M.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Harris CK, Kwong JY, Cohen MH, Bland DK, Fell GG, Nosé V, Bossuyt V. Changes in Surgical Pathology Case Volume and Amendment Rates During the COVID-19 Pandemic. Am J Clin Pathol. 2022 Feb 23. PMID: 35195696.
    Citations:    Fields:    
  2. Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. CECR2 drives breast cancer metastasis by promoting NF-?B signaling and macrophage-mediated immune suppression. Sci Transl Med. 2022 02 02; 14(630):eabf5473. PMID: 35108062.
    Citations: 1     Fields:    
  3. Koh SB, Dontchos BN, Bossuyt V, Edmonds C, Cristea S, Melkonjan N, Mortensen L, Ma A, Beyerlin K, Denault E, Niehoff E, Hirz T, Sykes DB, Michor F, Specht M, Lehman C, Ellisen LW, Spring LM. Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. NPJ Precis Oncol. 2021 Sep 21; 5(1):85. PMID: 34548623.
    Citations:    
  4. Bossuyt V, Lau R, Young B, Howe JG, Zhao F, Leyland-Jones B, Du L, Foli T, Hatzis C, Symmans WF. Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer. Clin Chem. 2021 09 01; 67(9):1240-1248. PMID: 34374711.
    Citations:    Fields:    
  5. Mortensen L, Ordulu Z, Dagogo-Jack I, Bossuyt V, Winters L, Taghian A, Smith BL, Ellisen LW, Kiedrowski LA, Lennerz JK, Bardia A, Spring LM. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion. Oncologist. 2021 10; 26(10):818-824. PMID: 34176200.
    Citations:    Fields:    Translation:Humans
  6. Chen PH, Bossuyt V, Reisenbichler E. Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions. Hum Pathol. 2021 02; 108:68-75. PMID: 33245988.
    Citations:    Fields:    Translation:HumansCells
  7. Beyerlin K, Jimenez R, Zangardi M, Fell GG, Edmonds C, Johnson A, Bossuyt V, Specht M, Mulvey TM, Moy B, Ellisen LW, Isakoff SJ, Bardia A, Spring LM. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. J Oncol Pharm Pract. 2021 Dec; 27(8):1883-1890. PMID: 33153384.
    Citations:    Fields:    Translation:Humans
  8. Xu X, Persing SM, Allam O, Park KE, Mozaffari MA, Lannin DR, Bossuyt V, Alperovich M. Management of recurrent bilateral multifocal pseudoangiomatous stromal hyperplasia (PASH). Breast J. 2020 09; 26(9):1814-1817. PMID: 32562297.
    Citations:    Fields:    Translation:Humans
  9. Bossuyt V, Spring L. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients. Breast J. 2020 06; 26(6):1189-1198. PMID: 32468652.
    Citations:    Fields:    Translation:Humans
  10. Reisenbichler ES, Han G, Bellizzi A, Bossuyt V, Brock J, Cole K, Fadare O, Hameed O, Hanley K, Harrison BT, Kuba MG, Ly A, Miller D, Podoll M, Roden AC, Singh K, Sanders MA, Wei S, Wen H, Pelekanou V, Yaghoobi V, Ahmed F, Pusztai L, Rimm DL. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Mod Pathol. 2020 09; 33(9):1746-1752. PMID: 32300181.
    Citations: 24     Fields:    Translation:Humans
  11. Rabe K, Snir OL, Bossuyt V, Harigopal M, Celli R, Reisenbichler ES. Interobserver variability in breast carcinoma grading results in prognostic stage differences. Hum Pathol. 2019 12; 94:51-57. PMID: 31655171.
    Citations: 5     Fields:    Translation:Humans
  12. Gupta S, Neumeister V, McGuire J, Song YS, Acs B, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL, Bossuyt V. Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer. NPJ Breast Cancer. 2019; 5:28. PMID: 31482108.
    Citations: 3     
  13. Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L. Immunological differences between primary and metastatic breast cancer. Ann Oncol. 2018 11 01; 29(11):2232-2239. PMID: 30203045.
    Citations: 78     Fields:    Translation:HumansCells
  14. Wilson PC, Chagpar AB, Cicek AF, Bossuyt V, Buza N, Mougalian S, Killelea BK, Patel N, Harigopal M. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score. Breast J. 2018 11; 24(6):976-980. PMID: 30230117.
    Citations: 5     Fields:    Translation:Humans
  15. Hofstatter EW, Horvath S, Dalela D, Gupta P, Chagpar AB, Wali VB, Bossuyt V, Storniolo AM, Hatzis C, Patwardhan G, Von Wahlde MK, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Increased epigenetic age in normal breast tissue from luminal breast cancer patients. Clin Epigenetics. 2018 08 29; 10(1):112. PMID: 30157950.
    Citations: 15     Fields:    Translation:HumansCells
  16. Gupta S, Mani NR, Carvajal-Hausdorf DE, Bossuyt V, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest. 2018 08; 98(8):1076-1083. PMID: 29858579.
    Citations: 5     Fields:    Translation:Humans
  17. Panse G, Bossuyt V, Ko CJ. Metastatic serous carcinoma presenting as inflammatory carcinoma over the breast-Report of two cases and literature review. J Cutan Pathol. 2018 Mar; 45(3):234-239. PMID: 29194708.
    Citations: 6     Fields:    Translation:Humans
  18. Bossuyt V. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting. Surg Pathol Clin. 2018 Mar; 11(1):213-230. PMID: 29413658.
    Citations: 4     Fields:    Translation:HumansCells
  19. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017 Nov; 24(6):311-335. PMID: 28777143.
    Citations: 178     Fields:    Translation:HumansCells
  20. Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2018 10; 52(Pt 2):16-25. PMID: 29024776.
    Citations: 106     Fields:    Translation:HumansCells
  21. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017 Sep; 24(5):235-251. PMID: 28777142.
    Citations: 154     Fields:    Translation:HumansAnimalsCells
  22. Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients: Results of a Randomized Controlled Trial. Ann Surg. 2017 01; 265(1):39-44. PMID: 27192352.
    Citations: 2     Fields:    Translation:Humans
  23. von Wahlde MK, Timms KM, Chagpar A, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pusztai L. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer. Clin Cancer Res. 2017 Mar 01; 23(5):1193-1199. PMID: 27601588.
    Citations: 13     Fields:    Translation:HumansCells
  24. Bossuyt V, Symmans WF. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy. Ann Surg Oncol. 2016 10; 23(10):3153-61. PMID: 27380637.
    Citations: 7     Fields:    Translation:Humans
  25. Bossuyt V, Hatzis C. The Neoadjuvant Model and Complete Pathologic Response in Breast Cancer: All or Nothing? JAMA Oncol. 2016 Jun 01; 2(6):760-1. PMID: 26914064.
    Citations:    Fields:    Translation:Humans
  26. Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein L, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt J, Shi W, Gershkovich P, Hatzis C, Pusztai L. Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. Oncotarget. 2016 Apr 19; 7(16):22064-76. PMID: 26980737.
    Citations: 6     Fields:    Translation:Humans
  27. Varadan V, Gilmore H, Miskimen KL, Tuck D, Parsai S, Awadallah A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris LN. Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. Clin Cancer Res. 2016 07 01; 22(13):3249-59. PMID: 26842237.
    Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
  28. Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. Breast Cancer Res Treat. 2015 Dec; 154(3):533-41. PMID: 26578401.
    Citations: 10     Fields:    Translation:Humans
  29. Varadan V, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KL, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, Bossuyt V, Lannin DR, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN. Brief-exposure to preoperative bevacizumab reveals a TGF-ß signature predictive of response in HER2-negative breast cancers. Int J Cancer. 2016 Feb 01; 138(3):747-57. PMID: 26284485.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  30. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015 Sep; 28(9):1185-201. PMID: 26205180.
    Citations: 66     Fields:    Translation:Humans
  31. Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med. 2015 Aug 06; 373(6):503-10. PMID: 26028131.
    Citations: 68     Fields:    Translation:Humans
  32. Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015 Jul; 26(7):1280-91. PMID: 26019189.
    Citations: 52     Fields:    Translation:Humans
  33. Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015 Apr; 3(4):326-32. PMID: 25527356.
    Citations: 144     Fields:    Translation:HumansCells
  34. Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014 Dec 01; 20(23):5995-6005. PMID: 25255793.
    Citations: 79     Fields:    Translation:HumansCells
  35. Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL. Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer. 2014 May 08; 14:326. PMID: 24885187.
    Citations: 14     Fields:    Translation:HumansCells
  36. Lindner R, Sullivan C, Offor O, Lezon-Geyda K, Halligan K, Fischbach N, Shah M, Bossuyt V, Schulz V, Tuck DP, Harris LN. Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. PLoS One. 2013; 8(11):e71915. PMID: 24260093.
    Citations: 39     Fields:    Translation:Humans
  37. Bossuyt V, Buza N, Ngo NT, Much MA, Asis MC, Schwartz PE, Hui P. Cancerous 'floater': a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability. Mod Pathol. 2013 Sep; 26(9):1264-9. PMID: 23558568.
    Citations: 2     Fields:    Translation:Humans
  38. Williams-Fritze MJ, Carlson Scholz JA, Bossuyt V, Booth CJ. Use of p63, a myoepithelial cell marker, in determining the invasiveness of spontaneous mammary neoplasia in a rhesus macaque (Macaca mulatta). J Am Assoc Lab Anim Sci. 2011 Mar; 50(2):252-7. PMID: 21439221.
    Citations: 3     Fields:    Translation:AnimalsCells
  39. Galanina N, Bossuyt V, Harris LN. Molecular predictors of response to therapy for breast cancer. Cancer J. 2011 Mar-Apr; 17(2):96-103. PMID: 21427553.
    Citations: 9     Fields:    Translation:Humans
  40. Gwin K, Wheeler DT, Bossuyt V, Tavassoli FA. Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases. Int J Surg Pathol. 2010 Feb; 18(1):27-35. PMID: 19282292.
    Citations: 5     Fields:    Translation:HumansCells
  41. Bossuyt V, Medeiros F, Drapkin R, Folkins AK, Crum CP, Nucci MR. Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma. Int J Gynecol Pathol. 2008 Jul; 27(3):390-7. PMID: 18580316.
    Citations: 1     Fields:    Translation:Humans
  42. He Q, Shkarin P, Hooley RJ, Lannin DR, Weinreb JC, Bossuyt VI. In vivo MR spectroscopic imaging of polyunsaturated fatty acids (PUFA) in healthy and cancerous breast tissues by selective multiple-quantum coherence transfer (Sel-MQC): a preliminary study. Magn Reson Med. 2007 Dec; 58(6):1079-85. PMID: 17969083.
    Citations: 18     Fields:    Translation:Humans
  43. Fadare O, Bossuyt V, Martel M, Parkash V. Primary osteosarcoma of the ovary: a case report and literature review. Int J Gynecol Pathol. 2007 Jan; 26(1):21-5. PMID: 17197892.
    Citations: 3     Fields:    Translation:Humans
  44. Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol. 2005 Oct; 13(4):319-27. PMID: 16273187.
    Citations: 11     Fields:    Translation:Humans
  45. Kim JH, Bossuyt V, Ponn T, Lannin D, Haffty BG. Cyclooxygenase-2 expression in postmastectomy chest wall relapse. Clin Cancer Res. 2005 Jul 15; 11(14):5199-205. PMID: 16033837.
    Citations: 2     Fields:    Translation:Humans
  46. Braet F, Vermijlen D, Bossuyt V, De Zanger R, Wisse E. Early detection of cytotoxic events between hepatic natural killer cells and colon carcinoma cells as probed with the atomic force microscope. Ultramicroscopy. 2001 Nov; 89(4):265-73. PMID: 11766982.
    Citations: 3     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bossuyt's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (205)
Explore
_
Co-Authors (25)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.